Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interactions Between Hydronidone and Entecavir in Healthy Volunteers
NCT04124081Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydronidone in Liver Fibrosis (LF) and Chronic Hepatitis B (CHB), sponsored by Gyre Pharmaceuticals. Primary endpoint: Plasma drug concentration. Started May 2019; status: completed.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04124081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124081.